Nanjing Xiangyuan Biopharmaceutical Technology

Nanjing Xiangyuan Biopharmaceutical Technology is a clinical-stage biotechnology company focused on the discovery and development of innovative small molecule therapeutics for oncology. The company leverages a proprietary structure-based drug design (SBDD) platform to target challenging protein-protein interactions and signaling pathways, particularly the RAS/MAPK pathway. Its lead programs include inhibitors targeting SHP2 and SOS1, which are currently being evaluated in clinical trials for various solid tumors. Xiangyuan Biopharmaceutical aims to provide precision medicine solutions by addressing unmet medical needs in cancer treatment through highly selective and potent chemical entities. The company is headquartered in Nanjing, China, and maintains a robust pipeline of early-stage assets targeting novel mechanisms in cancer biology.